OMCL - Omnicell Inc Stock Price, Fair Value and News

30.83USD+0.71 (+2.36%)Market Closed

Market Summary

USD30.83+0.71

Market Closed

2.36%

OMCL Alerts

Big fall in Revenue (Y/Y)

Losses in recent quarter

OMCL Stock Price

View Fullscreen

OMCL RSI Chart

OMCL Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-67.27

Price/Sales (Trailing)

1.28

EV/EBITDA

12.15

Price/Free Cashflow

7.95

OMCL Price/Sales (Trailing)

OMCL Profitability

Operating Margin

82.01%

EBT Margin

-1.52%

Return on Equity

-1.77%

Return on Assets

-0.92%

Free Cashflow Yield

12.57%

OMCL Fundamentals

OMCL Revenue

Revenue (TTM)

1.1B

Rev. Growth (Yr)

-15.3%

Rev. Growth (Qtr)

-4.9%

OMCL Earnings

Earnings (TTM)

-21.0M

Earnings Growth (Yr)

-4.51%

Earnings Growth (Qtr)

-9.05%

Breaking Down OMCL Revenue

Last 7 days

2.8%

Last 30 days

13.4%

Last 90 days

7.8%

Trailing 12 Months

-56.5%

How does OMCL drawdown profile look like?

OMCL Financial Health

Current Ratio

2.38

OMCL Investor Care

Shares Dilution (1Y)

1.87%

Diluted EPS (TTM)

-0.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.1B	0	0	0
2023	1.3B	1.2B	1.2B	1.1B
2022	1.2B	1.3B	1.3B	1.3B
2021	914.4M	987.5M	1.1B	1.1B
2020	924.2M	906.4M	891.3M	892.2M
2019	807.2M	835.9M	860.5M	897.0M
2018	746.8M	754.4M	771.9M	787.3M
2017	673.5M	681.6M	691.6M	712.7M
2016	539.3M	599.5M	651.0M	695.9M
2015	455.4M	463.1M	475.8M	484.6M
2014	395.2M	406.6M	425.1M	440.9M
2013	337.0M	355.3M	365.0M	380.6M
2012	252.5M	266.9M	286.8M	314.0M
2011	225.4M	231.7M	239.9M	245.5M
2010	0	216.4M	219.4M	222.4M
2009	0	0	0	213.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Omnicell Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	manley corey j	sold (taxes)	-2,298	27.69	-83.00	evp&chief legal/admin officer
Mar 15, 2024	spears joseph brian	sold (taxes)	-1,550	27.69	-56.00	chief accounting officer & svp
Feb 27, 2024	lipps randall a	acquired	-	-	107,251	chairman, president and ceo
Feb 27, 2024	etta nchacha	acquired	-	-	37,853	evp & cfo
Feb 27, 2024	manley corey j	acquired	-	-	31,965	evp&chief legal/admin officer
Feb 15, 2024	spears joseph brian	sold (taxes)	-3,905	28.3	-138	chief accounting officer & svp
Jan 30, 2024	voynick eileen j.	acquired	-	-	2,426	-
Jan 30, 2024	scott bruce e	acquired	-	-	51.00	-
Dec 15, 2023	lipps randall a	sold (taxes)	-246,127	38.26	-6,433	chairman, president and ceo
Dec 15, 2023	manley corey j	sold (taxes)	-8,493	38.26	-222	evp&chief legal/admin officer

Which funds bought or sold OMCL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	Summit Creek Advisors LLC	sold off	-100	-7,151,510	-	-%
May 10, 2024	VANGUARD GROUP INC	added	1.44	-44,452,400	165,200,000	-%
May 10, 2024	BlackRock Inc.	added	1.51	-62,766,800	234,030,000	-%
May 10, 2024	PNC Financial Services Group, Inc.	reduced	-9.05	-99,140	238,665	-%
May 10, 2024	FIRST NATIONAL BANK OF OMAHA	reduced	-64.54	-927,328	352,543	0.02%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-77.21	-628,714	135,244	-%
May 10, 2024	CREDIT SUISSE AG/	reduced	-84.16	-22,442,400	3,148,160	-%
May 10, 2024	CIBC Private Wealth Group, LLC	reduced	-9.71	-67,918	149,019	-%
May 10, 2024	PRINCIPAL SECURITIES, INC.	added	581	39,457	48,639	-%
May 10, 2024	ONTARIO TEACHERS PENSION PLAN BOARD	reduced	-47.01	-801,784	560,836	-%

Are Funds Buying or Selling OMCL?

Are funds buying OMCL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OMCL

No. of Funds

Unveiling Omnicell Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	12.25%	5,571,166	SC 13G/A
Jan 19, 2024	blackrock inc.	17.3%	7,887,234	SC 13G/A
Dec 11, 2023	wellington management group llp	0.26%	116,773	SC 13G/A
Sep 11, 2023	vanguard group inc	10.03%	4,532,732	SC 13G/A
Feb 09, 2023	vanguard group inc	9.92%	4,430,315	SC 13G/A
Feb 06, 2023	wellington management group llp	7.34%	3,277,600	SC 13G/A
Jan 23, 2023	blackrock inc.	12.8%	5,728,315	SC 13G/A
Feb 10, 2022	vanguard group inc	10.79%	4,740,493	SC 13G/A
Feb 04, 2022	wellington management group llp	5.76%	2,531,555	SC 13G/A
Jan 27, 2022	blackrock inc.	15.9%	6,983,442	SC 13G/A

Recent SEC filings of Omnicell Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 11, 2024	ARS	ARS
Apr 04, 2024	DEF 14A	DEF 14A
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Feb 29, 2024	8-K	Current Report
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading
Feb 29, 2024	4	Insider Trading

Peers (Alternatives to Omnicell Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	471.0B	379.5B	16.52%	4.18%	30.66	1.24	12.96%	-25.81%
CI	99.2B	206.0B	-0.19%	36.09%	25.74	0.48	12.55%	-43.95%
HCA	83.1B	66.7B	-1.75%	14.97%	15.19	1.25	9.59%	-4.59%
CVS	70.9B	360.9B	-17.72%	-17.64%	9.68	0.2	9.07%	78.49%
CNC	41.2B	155.5B	9.05%	14.83%	15.05	0.26	6.34%	84.42%
UHS	12.0B	14.7B	7.08%	28.00%	14.7	0.82	7.99%	19.23%
DVA	12.0B	12.3B	4.75%	45.76%	14.69	0.97	5.77%	58.74%
MID-CAP
CHE	8.6B	2.3B	-8.04%	3.95%	30.35	3.75	5.96%	18.29%
ACHC	6.6B	3.0B	-2.06%	0.60%	-588.47	2.22	10.92%	-104.06%
AMN	2.2B	3.5B	4.31%	-36.95%	15.6	0.64	-27.67%	-62.43%
AMEH	2.2B	1.5B	-3.93%	16.78%	35.11	1.51	19.34%	40.15%
SMALL-CAP
ADUS	1.8B	1.1B	13.13%	28.86%	27.6	1.67	11.45%	30.74%
BKD	1.3B	3.0B	8.04%	87.90%	-7.75	0.44	4.98%	4.88%
BEAT	52.7M	-	2.56%	-3.85%	-3.49	-	-	-1.05%
AMS	22.1M	21.3M	19.11%	26.45%	41.45	1.04	8.00%	-62.25%

Omnicell Inc News

Latest updates

Omnicell Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-4.9%	246	259	299	299	291	298	348	331	319	311	296	273	252	249	214	200	230	248	229	217	203
Gross Profit	-12.1%	93.00	105	132	134	125	122	159	158	150	149	147	136	122	124	97.00	83.00	110	124	112	104	97.00
Operating Expenses	-11.1%	114	129	128	127	148	160	141	146	145	138	117	107	103	103	87.00	90.00	97.00	101	88.00	85.00	84.00
S&GA Expenses	-9.4%	92.00	102	104	104	125	132	115	119	120	116	98.00	89.00	87.00	88.00	71.00	69.00	79.00	82.00	71.00	68.00	68.00
R&D Expenses	-17.8%	22.00	27.00	24.00	23.00	23.00	28.00	25.00	26.00	25.00	22.00	19.00	18.00	16.00	15.00	15.00	21.00	19.00	19.00	17.00	17.00	16.00
EBITDA Margin	8.0%	0.06*	0.06*	0.04*	0.05*	0.05*	0.07*	0.10*	0.10*	0.11*	0.12*	0.13*	0.13*	-	-	-	-	-	-	-	-	-
Income Taxes	46.9%	-2.20	-4.14	2.00	9.00	-6.18	-7.10	1.00	2.00	-3.24	-7.18	-5.99	3.00	-1.21	-2.50	2.00	-2.52	0.00	-0.12	3.00	1.00	8.00
Earnings Before Taxes	3.7%	-17.83	-18.52	7.00	12.00	-21.18	-35.51	17.00	11.00	5.00	7.00	23.00	23.00	13.00	14.00	11.00	-6.82	11.00	22.00	23.00	17.00	11.00
EBT Margin	13.3%	-0.02*	-0.02*	-0.03*	-0.02*	-0.02*	0.00*	0.03*	0.04*	0.05*	0.06*	0.07*	0.06*	-	-	-	-	-	-	-	-	-
Net Income	-9.1%	-15.68	-14.37	6.00	3.00	-15.00	-28.41	17.00	9.00	8.00	14.00	29.00	20.00	14.00	16.00	9.00	-4.30	11.00	22.00	20.00	16.00	3.00
Net Income Margin	-7.5%	-0.02*	-0.02*	-0.03*	-0.02*	-0.01*	0.00*	0.04*	0.05*	0.06*	0.07*	0.07*	0.06*	-	-	-	-	-	-	-	-	-
Free Cashflow	39.7%	41.00	29.00	46.00	61.00	3.00	68.00	8.00	-19.16	-27.48	49.00	36.00	66.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	2.6%	2,284	2,227	2,222	2,194	2,251	2,211	2,180	2,131	2,123	2,142	2,051	1,961	1,887	1,825	1,719	1,222	1,232	1,241	1,244	1,197	1,177
Current Assets	6.7%	990	928	914	881	935	882	849	788	776	781	889	984	904	829	963	465	478	483	477	430	414
Cash Equivalents	17.5%	550	468	447	399	340	330	266	245	265	349	482	614	548	490	629	134	104	127	137	87.00	77.00
Inventory	-6.0%	103	110	116	131	141	148	147	150	137	120	104	101	96.00	96.00	103	114	113	108	106	104	104
Net PPE	0.4%	109	109	107	103	98.00	94.00	88.00	82.00	77.00	71.00	65.00	62.00	61.00	59.00	58.00	58.00	53.00	54.00	55.00	53.00	52.00
Goodwill	-0.1%	735	736	734	736	735	734	731	734	740	739	616	499	499	499	160	335	335	337	335	336	336
Liabilities	5.5%	1,095	1,038	1,034	1,030	1,108	1,081	1,044	1,039	1,048	996	940	908	876	857	801	335	353	396	437	424	447
Current Liabilities	13.2%	416	368	369	370	454	428	377	374	951	876	339	317	292	276	234	237	248	237	228	211	211
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	50.00	77.00	77.00	97.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	50.00	77.00	77.00	97.00
Shareholder's Equity	0.0%	1,189	1,189	1,187	1,164	1,143	1,130	1,135	1,093	1,075	1,147	1,111	1,053	1,011	968	918	887	879	845	808	773	730
Retained Earnings	-4.2%	355	370	385	379	376	391	419	402	393	369	355	325	305	291	274	266	270	259	237	217	201
Additional Paid-In Capital	1.5%	1,139	1,122	1,110	1,089	1,073	1,047	1,031	998	983	1,025	1,003	971	950	920	892	821	808	781	770	753	725
Shares Outstanding	0.8%	46.00	46.00	45.00	45.00	45.00	45.00	44.00	44.00	44.00	43.00	43.00	43.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	3,300	-	-	-	5,000	-	-	-	6,500	-	-	-	3,000	-	-	-	3,500	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	30.0%	49,953	38,414	57,007	72,903	12,770	82,153	21,175	-9,551	-15,996	59,632	42,989	71,773	57,415	76,448	36,687	47,504	25,231	34,820	56,428	27,263	26,497
Share Based Compensation	-29.1%	8,641	12,187	14,982	14,089	14,042	17,516	17,310	17,213	16,208	14,683	13,666	13,039	11,772	11,663	11,024	11,351	10,659	8,874	8,505	8,260	8,410
Cashflow From Investing	0.3%	-12,340	-12,372	-14,187	-14,817	-13,640	-17,252	-15,867	-6,817	-18,733	-192,385	-193,631	-13,350	-13,132	-236,692	-9,961	-19,438	-13,775	-14,903	-14,811	-15,253	-16,697
Cashflow From Financing	-9.2%	11,926	13,130	2,825	3,603	3,862	3,562	9,056	-1,452	-32,119	6,666	18,284	6,814	15,599	20,399	468,178	1,458	-33,766	-30,524	8,628	-1,405	-178
Buy Backs	-	-	-	-	-	-	-	-	-	52,210	-	-	-	-	-	53,035	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OMCL Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues	$ 246,151	$ 290,629
Cost of revenues	153,528	165,600
Gross profit	92,623	125,029
Operating expenses:
Research and development	22,056	22,878
Selling, general, and administrative	92,414	125,114
Total operating expenses	114,470	147,992
Loss from operations	(21,847)	(22,963)
Interest and other income (expense), net	4,016	1,781
Loss before income taxes	(17,831)	(21,182)
Benefit from income taxes	(2,155)	(6,182)
Net loss	$ (15,676)	$ (15,000)
Net loss per share:
Basic (in dollars per share)	$ (0.34)	$ (0.33)
Diluted (in dollars per share)	$ (0.34)	$ (0.33)
Weighted-average shares outstanding:
Basic (in shares)	45,732	44,887
Diluted (in shares)	45,732	44,887
Product revenues
Revenues	$ 133,295	$ 185,715
Cost of revenues	92,441	109,527
Services and other revenues
Revenues	112,856	104,914
Cost of revenues	$ 61,087	$ 56,073

OMCL Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 512,364	$ 467,972
Accounts receivable and unbilled receivables, net of allowances of $6,463 and $5,564, respectively	248,512	252,025
Inventories	103,466	110,099
Prepaid expenses	26,585	25,966
Other current assets	98,991	71,509
Total current assets	989,918	927,571
Property and equipment, net	109,034	108,601
Long-term investment in sales-type leases, net	43,909	42,954
Operating lease right-of-use assets	26,531	24,988
Goodwill	735,357	735,810
Intangible assets, net	205,115	211,173
Long-term deferred tax assets	37,383	32,901
Prepaid commissions	50,191	52,414
Other long-term assets	86,317	90,466
Total assets	2,283,755	2,226,878
Current liabilities:
Accounts payable	43,145	45,028
Accrued compensation	41,446	51,754
Accrued liabilities	167,187	149,276
Deferred revenues	164,586	121,734
Total current liabilities	416,364	367,792
Long-term deferred revenues	65,195	58,622
Long-term deferred tax liabilities	1,493	1,620
Long-term operating lease liabilities	34,568	33,910
Other long-term liabilities	7,099	6,318
Convertible senior notes, net	570,439	569,662
Total liabilities	1,095,158	1,037,924
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value, 5,000 shares authorized; no shares issued	0	0
Common stock, $0.001 par value, 100,000 shares authorized; 56,207 and 55,822 shares issued; 45,924 and 45,539 shares outstanding, respectively	56	56
Treasury stock at cost, 10,283 shares outstanding, respectively	(290,319)	(290,319)
Additional paid-in capital	1,139,010	1,122,292
Retained earnings	354,681	370,357
Accumulated other comprehensive loss	(14,831)	(13,432)
Total stockholders’ equity	1,188,597	1,188,954
Total liabilities and stockholders’ equity	$ 2,283,755	$ 2,226,878

About Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Santa Clara, California.

CEO	Mr. Randall A. Lipps
WEBSITE	omnicell.com
INDUSTRY	Healthcare Plans
EMPLOYEES	3780

Omnicell Inc Frequently Asked Questions

What is the ticker symbol for Omnicell Inc? What does OMCL stand for in stocks?

OMCL is the stock ticker symbol of Omnicell Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Omnicell Inc (OMCL)?

As of Mon May 13 2024, market cap of Omnicell Inc is 1.42 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OMCL stock?

You can check OMCL's fair value in chart for subscribers.

What is the fair value of OMCL stock?

You can check OMCL's fair value in chart for subscribers. The fair value of Omnicell Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Omnicell Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OMCL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Omnicell Inc a good stock to buy?

The fair value guage provides a quick view whether OMCL is over valued or under valued. Whether Omnicell Inc is cheap or expensive depends on the assumptions which impact Omnicell Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OMCL.

What is Omnicell Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, OMCL's PE ratio (Price to Earnings) is -67.27 and Price to Sales (PS) ratio is 1.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OMCL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Omnicell Inc's stock?

In the past 10 years, Omnicell Inc has provided 0.016 (multiply by 100 for percentage) rate of return.